SMC Laboratories is highly regarded worldwide as a consulting CRO that designs studies in line with the demands of pharmaceutical companies and research institutions.
In particular, in the MASH/NASH field, SMC is a highly regarded CRO, because of our unique STAM™ mice.
The results achieved with our STAM™ have been introduced in academic publications as well as scientific conferences.


2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023



AASLD 2011,

“The Dipeptidyl Peptidase-4 Inhibitor Linagliptin is an Effective Therapeutic for Metabolic Liver Disease in Several Rodent Models of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)” Boehringer Ingelheim GmbH & Co. KG



EASL Special Conference – Liver Transplantation 2011,

“Improvement of steatosis, inflammation, and fibrosis in a mouse model of steatohepatitis following treatment with galectin inhibitor” Galectin Therapeutics Inc.